RNA, U5B small nuclear 2, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU5B-2P profile across patient tissues and cancer cell-line models. RNU5B-2P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RNU5B-2P is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, RNU5B-2P RNA expression shows 14,917 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BLCA, COAD, and ESCA as cancer lineages where RNU5B-2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU5B-2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU5B-2P survival associations across molecular data types. RNU5B-2P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU5B-2P RNA expression–survival associations across cancer types. High RNU5B-2P expression shows unfavorable associations in KIRC, but favorable associations in BLCA, PAAD, SKCM, STAD and CESC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RNU5B-2P RNA expression.
This table summarizes RNU5B-2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU5B-2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU5B-2P shows lower tumor expression in COAD, UCEC and LUSC and higher tumor expression in LIHC, BLCA and KIRC. The COAD box plot shows higher RNU5B-2P RNA expression in normal versus tumor tissue (log2 FC = −0.863, t-test p = .002).
This table shows molecular features associated with RNU5B-2P in patient tissues and cancer cell lines. In patient samples, RNU5B-2P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
